Demergers, which are expected to unlock shareholder value, have not worked in favour of shareholders of Omkar Speciality Chemicals and Lasa Supergenerics.
Omkar Speciality Chemicals Limited (Omkar Chemical) incorporated in 2005, is in the business of speciality chemicals & active pharmaceutical ingredient (API). The business was carried out by Omkar Chemical by its own and through its 4 subsidiary companies. API business was carried out in company’s subsidiary Lasa Laboratory Pvt Ltd (Lasa Lab).
In 2015, director of Omkar Chemical have approved the scheme of arrangement under which all subsidiary companies will be merged into Omkar Chemical and demerger of its API business to “Lasa Super generic Ltd” (company incorporated by Omkar chemical for the purpose of demerger of API division) with the appointed date being 01/04/2015. Scheme was approved by NCLT in April 2017.
Post demerger, Omkar chemical and Lasa Supergenre business collapsed and both the company facing liquidity challenges as well as potential Insolvency process threat. In this article, we analyzed the company’s financials from Mar-12 onward to understand what went wrong which lead to current situation.
Transaction in 2015
Financial Analysis: Omkar Chemical
Already a user? Sign in